Isofol Medical AB (publ) publishes year-end report, January – December 2025

The information in the press release is intended for investors.

CEO’s comments
"As our clinical study of arfolitixorin progresses, Isofol has participated in several scientific congresses in the US and Europe, and we note a significant interest in our drug candidate. While the field of cancer therapeutics is advancing rapidly, innovations in first-line treatment for metastatic colorectal cancer remain limited – positioning arfolitixorin to fill an important unmet need also in the future. With each quarter, we move closer to our goal: to improve cancer treatment for millions of patients while creating substantial value for shareholders, employees, and society,” says CEO Petter Segelman Lindqvist.

Fourth quarter, October – December 2025

• Net revenue amounted to kSEK 0 (0)
• The result for the period amounted to kSEK -12,777 (-13,102)
• Earnings per share amounted to SEK -0.05 (-0.08)
• Cash and cash equivalents on December 31 amounted to kSEK 126,990 (96,157)

January – December 2025

• Net revenue amounted to kSEK 0 (0)
• The result for the period amounted to kSEK -54,168 (-43,488)
• Earnings per share amounted to SEK -0.25 (-0.27)
• The Board of Directors proposes that no dividend will be paid for the 2025 financial year

Significant events during the fourth quarter

• On October 16, Isofol announced that the company participated in the ESMO cancer congress in Berlin, where an abstract describing the study design of Isofol's ongoing clinical phase Ib/II study was presented as an ePoster.
• On November 13, Isofol announced that the European Patent Office (EPO) has issued an "Intention to Grant" for a new product patent for the company's cancer drug candidate arfolitixorin. Patent protection is thus secured until 2043.

Significant events after the end of the period

• On January 9, 2026, Isofol announced that the company participated in the ASCO-GI cancer meeting in the USA, where a TiP abstract (Trial in Progress) describing the study design of Isofol's ongoing phase Ib/II clinical study was presented.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56

Margareta Hagman, CFO
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0)738 73 34 18

The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on February 18, 2026.

About Isofol
Isofol works to improve the quality of life and prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com